This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Primary CNS lymphoma (PCNSL) is an infiltrative, primarily large B-cell lymphoma confined to the CNS or eyes at the time of diagnosis, with an incidence of 5 per million. Because of its rarity, phase III trials to determine the best treatment regimen have been difficult to perform and no single standard of care exists. Current guidelines suggest initial high-dose methotrexate-based (HDMTX) chemotherapy is the most active regimen. In general, 3 first-line chemotherapy treatment approaches are currently used by most PCNSL investigators: (1) HDMTX-based chemotherapy with or without subsequent whole-brain radiotherapy (WBRT); (2) induction HDMTX-based chemotherapy followed by high-dose chemotherapy consolidation with or without autologous stem cell transplantation1; and (3) standard dose HDMTX-based chemotherapy with mechanisms to increase delivery to the CNS such as blood–brain barrier disruption (BBBD).2
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 1242
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Management and outcome of primary CNS lymphoma in the modern era